Stock 4TZ ORIC PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News ORIC Pharmaceuticals, Inc. Börse Stuttgart

Equities

4TZ

US68622P1093

Market Closed - Börse Stuttgart
Other stock markets
 15:14:10 28/06/2024 BST 		5-day change 1st Jan Change
6.5 EUR +3.17% Intraday chart for ORIC Pharmaceuticals, Inc. -4.41% -20.25%
06-10 Transcript : ORIC Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM
05-06 ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : ORIC Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
GL
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
GL
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
AQ
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer
MT
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
GL
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
CI
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
GL
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
AQ
ORIC Pharmaceuticals, Inc Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research Annual Meeting
CI
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
GL
JPMorgan Trims ORIC Pharmaceuticals' Price Target to $18 From $19, Maintains Overweight Rating
MT
HC Wainwright Adjusts ORIC Pharmaceuticals' Price Target to $21 From $15, Keeps Buy Rating
MT
ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) added to S&P Biotechnology Select Industry Index
CI
Baird Cuts Price Target on ORIC Pharmaceuticals to $25 From $27, Maintains Outperform Rating
MT
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ORIC Stock
  4. 4TZ Stock
  5. News ORIC Pharmaceuticals, Inc.